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ABSTRACT CXCR2 is a chemokine receptor expressed on oligodendroglia that has
been implicated in the pathogenesis of neuroinﬂammatory demyelinating diseases
as well as enhancement of the migration, proliferation, and myelin production by
oligodendroglia. Using an inducible proteolipid protein (Plp) promoter-driven Cre-
loxP recombination system, we were able to assess how timed ablation of Cxcr2 in
oligodendroglia affected disease following intracranial infection with the neurotropic
JHM strain of mouse hepatitis virus (JHMV). Generation of Plp-Cre-ER(T)::Cxcr2ﬂox/ﬂox
transgenic mice (termed Cxcr2-CKO mice) allows for Cxcr2 to be silenced in oligo-
dendrocytes in adult mice following treatment with tamoxifen. Ablation of oligoden-
droglia Cxcr2 did not inﬂuence clinical severity in response to intracranial infection
with JHMV. Inﬁltration of activated T cells or myeloid cells into the central nervous sys-
tem (CNS) was not affected, nor was the ability to control viral infection. In addition, the
severity of demyelination was similar between tamoxifen-treated mice and vehicle-
treated controls. Notably, deletion of Cxcr2 resulted in increased remyelination, as as-
sessed by g-ratio (the ratio of the inner axonal diameter to the total outer ﬁber diame-
ter) calculation, compared to that in vehicle-treated control mice. Collectively, our
ﬁndings argue that CXCR2 signaling in oligodendroglia is dispensable with regard to
contributing to neuroinﬂammation, but its deletion enhances remyelination in a preclini-
cal model of the human demyelinating disease multiple sclerosis (MS).
IMPORTANCE Signaling through the chemokine receptor CXCR2 in oligodendroglia is
important for developmental myelination in rodents, while chemical inhibition or non-
speciﬁc genetic deletion of CXCR2 appears to augment myelin repair in animal models
of the human demyelinating disease multiple sclerosis (MS). To better understand the
biology of CXCR2 signaling on oligodendroglia, we generated transgenic mice in which
Cxcr2 is selectively ablated in oligodendroglia upon treatment with tamoxifen. Using a
viral model of neuroinﬂammation and demyelination, we demonstrate that genetic si-
lencing of CXCR2 on oligodendroglia did not affect clinical disease, neuroinﬂammation,
or demyelination, yet there was increased remyelination. These ﬁndings support and ex-
tend previous ﬁndings suggesting that targeting CXCR2 may offer a therapeutic avenue
for enhancing remyelination in patients with demyelinating diseases.
KEYWORDS chemokine receptors, demyelination, oligodendrocyte, remyelination,
virus
Multiple sclerosis (MS) is a chronic inﬂammatory neurodegenerative disease char-acterized by multifocal regions of central nervous system (CNS) neuroinﬂamma-
tion, demyelination, and axonal loss that ultimately results in extensive neurologic
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disability (1). Preclinical animal models of MS indicate that CNS inﬁltration of neutro-
phils, monocyte/macrophages, and inﬂammatory T cells, including those that are
autoreactive to speciﬁc proteins embedded in the myelin sheath, is important in
disease initiation and maintaining demyelination. Through the use of mouse models of
MS, chemokines and chemokine receptors have been implicated as being important in
attracting targeted populations of activated immune cells into the CNS and have been
considered relevant targets for clinical intervention for MS patients (2–11). CXCR2 is a
receptor for ELR-positive CXC chemokines, e.g., CXCL1 and CXCL2, and is expressed on
polymorphonuclear neutrophils (PMN) as well as glia (12–16). CXCR2 signaling on
neutrophils promotes demyelination in models of experimental autoimmune enceph-
alomyelitis (EAE), cuprizone-induced demyelination, as well as virus-induced demyeli-
nation (8, 17–19). However, CXCR2 has additional roles that extend beyond inﬂuencing
neutrophil activity, as it is expressed on immature oligodendrocyte progenitor cells
(OPCs) as well as mature myelinating oligodendrocytes (20). In vitro studies have
demonstrated that signaling through CXCR2 inﬂuences OPC proliferation and differen-
tiation (21), whereas in vivo studies argue that CXCR2 controls the positional migration
of OPCs within the spinal cord and regulates OPC numbers to ensure the structural
integrity of the white matter during CNS development (22). Indeed, mice devoid of
CXCR2 exhibit a paucity of OPCs and structural misalignments that persist into adult-
hood of the mouse, resulting in reduced numbers of mature oligodendrocytes and total
myelin within the white matter (23). Moreover, either genetic deletion or antibody-
mediated targeting of CXCR2 increases myelin synthesis in demyelinated cerebellum
slice cultures (24). The concept of CXCR2 signaling on oligodendroglia regulating
myelin synthesis is further supported by a recent report by Liu and colleagues (25) that
demonstrated that targeted ablation of CXCR2 on oligodendroglia enhanced remyeli-
nation following toxin-induced demyelination. Collectively, these ﬁndings argue that
CXCR2 signaling on oligodendroglia ultimately contributes to maintaining myelin
integrity and axonal protection both under homeostatic conditions and following
demyelination.
Intracranial (i.c.) inoculation of susceptible mice with the neurotropic JHM strain of
mouse hepatitis virus (JHMV) results in an acute encephalomyelitis characterized by
widespread viral replication in glial cells with relative sparing of neurons (26, 27).
CNS-inﬁltrating CD4 and CD8 T cells control viral replication through the secretion
of gamma interferon (IFN-) and cytolytic activity, yet sterile immunity is not acquired
and virus persists in white matter tracts, resulting in an immune-mediated demyelinat-
ing disease with clinical and histologic similarities to the human demyelinating disease
MS (28, 29). Previous studies employing the JHMV model have demonstrated important
roles for select chemokines in participating in host defense as well as demyelination by
attracting targeted populations of leukocytes into the CNS (30–36). More recently, we have
shown that treatment of JHMV-infected mice with blocking antibody speciﬁc for CXCR2 led
to an increase in clinical disease associated with more severe demyelination (37). Exami-
nation of spinal cords revealed that the increase in white matter damage in anti-CXCR2-
treated mice was associated with oligodendroglia apoptosis, arguing for a protective role
for CXCR2 signaling in a model of virus-induced demyelination (37). Nonetheless, other
resident cells as well as inﬂammatory cells express CXCR2, making it difﬁcult to assign a
speciﬁc role for CXCR2 signaling on oligodendroglia in contributing to either protection or
disease progression. The present study was undertaken to better understand how selective
deletion of Cxcr2 within oligodendroglia lineage cells in adult mice inﬂuences host defense
and disease in response to JHMV infection of the CNS.
RESULTS
Generation and characterization of Cxcr2-CKO mice. We sought to ablate Cxcr2
signaling within oligodendrocytes and their progenitors to assess the impact on disease
and repair in an animal model of neuroinﬂammation and demyelination. A Plp-Cre-
ER(T)::Cxcr2ﬂox/ﬂox mouse line (referred to as Cxcr2-CKO) that utilizes Cre recombinase to
ablate Cxcr2 in a selective and inducible manner was employed (17, 38–41). The
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proteolipid protein (PLP) regulatory element promotes expression of Cre-ER(T) (42) and
has previously been shown to accurately reﬂect endogenous PLP expression spatially
and temporally in oligodendroglia (42). To aid in visualizing cells actively expressing Cre
recombinase, Cxcr2-CKO mice were crossed to a Cre-inducible Rosa26-tdTomato re-
porter line on the C57BL/6 mouse background (Fig. 1A). Ablation of Cxcr2 was con-
ﬁrmed within oligodendrocyte lineage cells following ex vivo culture of oligodendroglia
generated from the brains of postnatal day 1 (P1) Cxcr2-CKO mice. Addition of (Z)-4-
hydroxytamoxifen (4-OHT; 100 nM) induced Cre-mediated recombination at the Cxcr2
locus, as detected by PCR using primers that speciﬁcally generate an amplicon follow-
ing excision of exon 2 of Cxcr2 (Fig. 1B). 4-OHT induced expression of tdTomato red in
the majority of cultured cells from the brains of P1 Cxcr2-CKO mice at day 6 posttreat-
ment, with the tdTomato red being distributed throughout the cell body and the cell
morphology resembling oligodendrocytes (Fig. 1C). Immunocytochemical staining re-
vealed 90% of cultured oligodendroglia expressing the late-stage O1 surface marker,
in contrast to vehicle-treated cultures (Fig. 1D).
Tamoxifen treatment results in enriched tdTomato red expression in spinal
cord oligodendroglia. To determine the cellular speciﬁcity of Cre activity in vivo,
4-week-old Cxcr2-CKO mice were treated with 1 mg tamoxifen by intraperitoneal (i.p.)
administration twice daily for 5 days, and the targeting of Cxcr2 was subsequently
determined (43, 44). Recombination at the Cxcr2 locus was detected by PCR in the brain
and spinal cord of Cxcr2-CKO mice but not in the spleen, liver, or kidney (Fig. 2A). In
response to tamoxifen treatment, there was a dramatic increase in tdTomato expres-
sion that was distributed throughout the cell body as well as processes. To identify cells
expressing tdTomato within the CNS in response to tamoxifen treatment, immunohis-
tochemical staining for deﬁned cellular markers of the CNS was performed. In addition
to oligodendroglia, we focused our attention on neurons (45, 46) and macrophages/
microglia (45, 47), as these cells have been reported to express CXCR2. Expression of
FIG 1 Cre-mediated recombination is detected in vitro. (A) Schematic diagram showing the genetic strategy used to generate tamoxifen-inducible knockout
of Cxcr2 within oligodendroglia. (B) Cre-mediated recombination at the Cxcr2 locus was detected by PCR from oligodendroglia-enriched cultures derived from
postnatal day 1 (P1) Cxcr2-CKO mice following addition of 100 nM (Z)-4-hydroxytamoxifen (4-OHT). gDNA, genomic DNA. (C) Representative immunoﬂuorescent
staining for O1 (a marker for mature oligodendrocytes) from cultured oligodendroglia following 6 days of treatment with 4-OHT, showing a morphology
characteristic of mature oligodendrocytes and colocalization of O1 (green) and tdTomato red. (D) Treatment of cultured oligodendroglia with 4-OHT resulted
in expression of tdTomato in 90% of O1-positive oligodendrocytes (****, P 0.0001; 91.4%  2.02%) derived from P1 Cxcr2-CKO mice, in contrast to vehicle
treatment (3.92%  0.14%); data are presented as the average  SEM and represent those from 3 independent experiments.
CXCR2 and Myelin Repair Journal of Virology
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CXCR2 by astrocytes has not been reported, and we did not concentrate on this
population of cells (48, 49). We found that the majority of tdTomato-positive cells in
tamoxifen-treated Cxcr2-CKO mice were oligodendroglia, as deﬁned by staining either
oligodendrocyte transcription factor 2 (Olig2) (50, 51) or glutathione S-transferase 
FIG 2 Cxcr2 is ablated in vivo following tamoxifen treatment. (A) Detection of Cre-mediated recombination at the Cxcr2
locus in the brain and spinal cord of Cxcr2-CKO mice 2 weeks following tamoxifen treatment. (B to E) Phenotyping of
tdTomato-positive cells was performed via immunoﬂuorescent staining for deﬁned cell-speciﬁc markers. Represen-
tative staining of spinal cords from tamoxifen-treated (n 5) Cxcr2-CKO mice for oligodendroglia via GST- (B), Olig2
(C), neurons (MAP2) (D), and macrophage/microglia (IBA1) (E). Magniﬁcations,20. Arrows in panels B and C represent
dual-positive cells. (F) Quantiﬁcation of dual-positive cells in the spinal cords of tamoxifen-treated mice; the data were
derived from 2 independent experiments, with the data presented as the average  SEM. (G) The surface expression
of CXCR2 on neutrophils was not affected in tamoxifen-treated Cxcr2-CKO mice (n 2), in contrast to the vehicle-
treated controls (n 2); the data are presented as the average  SEM. MFI, mean ﬂuorescence intensity.
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(GST-), a marker of mature oligodendrocytes (52, 53). In tamoxifen-treated mice,
82% of tdTomato-positive cells (cells in which the tdTomato signal was distributed
throughout the cell body) expressed nuclear-speciﬁc markers (Olig2, 42.1%  7.7%;
GST-, 39.9%  7.9%) (Fig. 2B, C, and F). MAP2-positive neurons accounted for 4% of
tdTomato-positive cells (3.3%  0.8%) in tamoxifen-treated Cxcr2-CKO mice (Fig. 2D
and F). Similarly, very few IBA1-positive macrophages/microglia expressed tdTomato
(2.6%  0.3%) (Fig. 2E and F). We have previously demonstrated that neutrophils
require CXCR2 to trafﬁc and accumulate within the CNS in response to JHMV infection
(54). Tamoxifen treatment did not modulate CXCR2 expression in neutrophils, as no
differences were observed in surface expression of CXCR2 on splenic neutrophils
obtained from tamoxifen-treated Cxcr2-CKO mice and vehicle-treated mice, as deter-
mined by ﬂow cytometry (Fig. 2G). These results demonstrate that tamoxifen-induced
targeting of Cxcr2 is highly speciﬁc to oligodendrocyte lineage cells. It is important to
note that we did not perform CXCR2 immunohistochemical staining in experimental
tissues, as we have previously reported that there are no validated CXCR2-speciﬁc
antibodies, as we routinely detected nonspeciﬁc CXCR2 staining in experimental
Cxcr2	/	 mice (24). The remaining tdTomato-positive cells present within the spinal
cords of tamoxifen-treated mice (12%) most likely represent oligodendroglia cellular
processes extending from the cell bodies in which neither Olig2 or GST- is detected.
No defects in myelin formation/synthesis following Cxcr2 ablation in oligoden-
droglia. We next evaluated whether tamoxifen-mediated targeting of Cxcr2 in oligo-
dendroglia in adult mice affected myelin integrity, as previous studies have indicated
that adult Cxcr2	/	 animals have deﬁcient myelin formation (22, 23). Cxcr2-CKO mice
were treated twice daily with either 1 mg tamoxifen or vehicle, followed by resting for
2 weeks, at which point the spinal cords were removed to evaluate spinal cord myelin.
Similar to the ﬁndings of Liu et al. (25), we did not detect any differences in either the
size or behavior in tamoxifen-treated Cxcr2-CKO mice compared to their vehicle-treated
littermates. Assessment of spinal cord myelin via toluidine blue staining revealed no
overt differences between tamoxifen-treated Cxcr2-CKO mice and vehicle-treated con-
trol Cxcr2-CKO mice (Fig. 3A and B). As an additional test of myelin integrity, electron
microscopy (EM) analysis of spinal cord sections was performed. Assessment of the g
ratio, the ratio of the inner axonal diameter to the total outer ﬁber diameter, is
commonly employed as a structural index of myelin. We did not detect any changes in
qualitative differences in myelin thickness between naive tamoxifen-treated Cxcr2-CKO
mice and vehicle-treated Cxcr2-CKO mice (Fig. 3C and D); subsequent calculation of the
g ratios between experimental groups conﬁrmed that targeting of CXCR2 in oligoden-
droglia in adult mice did not alter myelin integrity (Fig. 3E and F). In all experimental
groups, the g ratios averaged 0.8, indicating normal myelinated axons in the spinal
cord (Fig. 3E and F) (55–57). These ﬁndings argue that inducible deletion of CXCR2 in
oligodendroglia lineage cells in young (4-week-old) mice does not affect the myelin
content in a nondisease state.
Cxcr2 ablation within oligodendrocytes does not impair antiviral responses.
Intracranial (i.c.) instillation of the neuroadapted JHM strain of mouse hepatitis virus
(JHMV) results in an acute encephalomyelitis followed by a chronic demyelinating
disease characterized by viral persistence in white matter tracts accompanied by
immune-mediated demyelination (26). Tamoxifen- or vehicle-treated Cxcr2-CKO mice
were infected i.c. with JHMV (250 PFU), and clinical disease was monitored. Vehicle-
treated Cxcr2-CKO mice had worse (P 0.05) clinical disease at 12 days postinfection
(p.i.) than control mice, but otherwise, no overt differences in morbidity or mortality
were observed in the experimental mice out to day 28 p.i. (Fig. 4A). Examination of the
viral titers in the brains at days 5, 7, and 10 p.i. showed similar levels of virus present
between tamoxifen- and vehicle-treated mice (Fig. 4B). Although the titers were higher
(P 0.05) in tamoxifen-treated animals at day 7 p.i. than in the controls, we do not
believe that this reﬂects an overall difference in the control of viral replication, as there
were no differences in viral titers between experimental groups at the other time points
examined. By day 21 p.i., virus was not detected (ND) in the brains of experimental mice
CXCR2 and Myelin Repair Journal of Virology
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(Fig. 4B). There were no differences in viral titers in the spinal cords of experimental
mice at days 5, 7, and 10 p.i. (Fig. 4B). Collectively, these ﬁndings indicate that Cxcr2
targeting did not compromise the control of viral replication within the CNS. Moreover,
similar frequencies of CD4 and CD8 T cells speciﬁc for the immunodominant viral
epitopes M133-144 and S510-518, respectively, as determined by tetramer staining,
were detected within the brains of the experimental mice at day 7, further supporting
that targeting of Cxcr2 within oligodendroglia did not impact the generation of a
protective antiviral immune response (Fig. 4C). There were no differences in either total T
cell subsets, neutrophils (CD11b Ly6G), or macrophages (CD45hi F4/80hi) at day 7 p.i.
between vehicle- and tamoxifen-treated mice (Fig. 4D). The comparable acute inﬂamma-
tory response to JHMV between vehicle- and tamoxifen-treated Cxcr2-CKOmice was further
supported by the observation of no signiﬁcant differences in expression of proinﬂamma-
tory cytokine and chemokine genes (a detailed inventory of the probes is provided in
Materials and Methods) within the brain at day 7 p.i. (Fig. 4E). Collectively, these ﬁndings
indicate that selectively targeting Cxcr2 within oligodendroglia does not mute neuroin-
ﬂammation or impair control of JHMV replication within the CNS.
FIG 3 Myelin integrity and ultrastructure are not affected following tamoxifen-treatment of naive Cxcr2-CKO
mice. Cxcr2-CKO mice were treated with either vehicle or tamoxifen for 1 week and sacriﬁced 2 weeks later
to evaluate myelin integrity. (A and B) Representative spinal cord semithin sections stained with toluidine blue
demonstrate no visible differences in myelin between vehicle-treated (A) and tamoxifen-treated (B) mice. (C
and D) Representative EM images showingmyelinated axons within the spinal cords of vehicle-treated (C) and
tamoxifen-treated (D) Cxcr2-CKO mice. Analysis was performed in the ventral and lateral white matter tracts.
Magniﬁcations, 1,200. (E) Scatter plot depicting the g ratios of individual axons as a function of the axonal
diameter. (F) Calculation of the g ratios of vehicle-treated (n 3, 0.75 0.004, 222 axons) and tamoxifen-
treated (n 3, 0.75 0.004, 298 axons) Cxcr2-CKO mice. The data were derived from two independent
experiments with 2 to 4 mice per group and are presented as the mean  SEM.
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Cxcr2 ablation does not affect the severity of demyelination. JHMV infection of
mice results in persistent CNS infection and a chronic immune-mediated demyelinating
disease. Evaluation of demyelination in JHMV-infected Cxcr2-CKO mice indicated that
there were no signiﬁcant differences in the severity of demyelination between vehicle-
and tamoxifen-treated Cxcr2-CKO mice at days 21 (Fig. 5A to C) and 28 (Fig. 5E to G) p.i.
Evaluation of immune cell inﬁltration into the spinal cords of tamoxifen- and vehicle-
treated mice by ﬂow cytometry at either day 21 p.i. (Fig. 5D) or day 28 p.i. (Fig. 5H)
revealed no difference in CD4 or CD8 T cell as well as macrophage (CD45lo F4/80)
inﬁltration. Furthermore, examination of demyelination within the brains of JHMV-
infected Cxcr2-CKO mice treated with either vehicle or tamoxifen revealed no differ-
ences in the severity of demyelination (data not shown). These ﬁndings argue that
tamoxifen-mediated targeting of Cxcr2 within oligodendroglia does not alter immune
cell inﬁltration into the spinal cords of JHMV-infected mice or inﬂuence the severity of
white matter damage.
FIG 4 Tamoxifen-treated Cxcr2-CKO mice are susceptible to JHMV-induced neuroinﬂammation. Cxcr2-CKO mice were treated with either tamoxifen (n 22) or
vehicle (n 10), rested for 2 weeks, and infected i.c. with 250 PFU of JHMV. The data are representative of those from 3 independent experiments. (A) Clinical
disease developed in both groups, and vehicle-treated Cxcr2-CKO mice had worse (P 0.05) disease at 12 days p.i. than control mice, but otherwise, there were
no statistically signiﬁcant differences in disease severity or mortality out to day 28 p.i. between the experimental groups. (B) Viral titers in the brains and spinal
cords of tamoxifen- and vehicle-treated mice at days 5, 7, and 10 p.i. *, P 0.05. By day 21 p.i., virus was not detected (ND) in the brains of experimental mice.
dpi, day postinfection. (C) No differences in the frequencies of virus-speciﬁc CD4 and CD8 T cells were detected, as determined by tetramer staining at day
7 p.i. (D) At day 7 p.i., similar numbers of neutrophils (Neut.), macrophages (Mac.), and T cells were detected in the brains of JHMV-infected Cxcr2-CKO mice
treated with either vehicle or tamoxifen. Day 7 p.i. ﬂow cytometric data were derived from 2 independent experiments with a minimum of 3 mice per group
for each experiment. (E) RNA analysis revealed no changes in proinﬂammatory gene expression within the brains of the experimental groups at day 7 p.i. The
data represent the average for 2 mice per group.
CXCR2 and Myelin Repair Journal of Virology
September 2019 Volume 93 Issue 18 e00240-19 jvi.asm.org 7
 o
n
 February 20, 2020 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
Remyelination is enhanced upon silencing of CXCR2 in oligodendroglia. Previ-
ous work has indicated that targeting of CXCR2 signaling through either adminis-
tration of receptor-speciﬁc small molecules (58) or genetic targeting (25) results in
increased remyelination. To determine whether remyelination was occurring following
tamoxifen-mediated silencing of Cxcr2 signaling, JHMV-infected Cxcr2-CKO mice were
FIG 5 Demyelination is not affected following Cxcr2 ablation. JHMV-infected Cxcr2-CKO mice were
treated with vehicle or tamoxifen and sacriﬁced at days 21 and 28 p.i., and spinal cords were removed
to assess the severity of demyelination. Representative spinal cords from either vehicle-treated (A, E) or
tamoxifen-treated (B, F) mice were collected at day 21 p.i. (A and B) or day 28 p.i. (E and F) and stained
with Luxol fast blue (LFB). Quantiﬁcation of the severity of demyelination revealed no differences at
either day 21 p.i. (C) or day 28 p.i. (G). Flow cytometric data revealed no differences in spinal cord
inﬁltration of T cells (CD4 and CD8 subsets) or macrophages (CD45hi F4/80) at either day 21 p.i. (D)
or day 28 p.i. (H). The data were derived from two independent experiments with 2 to 3 mice per group
and are presented as the mean  SEM.
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sacriﬁced at day 28 p.i., and EM analysis of spinal cord sections was performed to
calculate g ratios. High-magniﬁcation (1,200) images of the spinal cord lateral white
matter columns concentrated within thoracic vertebrae 6 to 10 of tamoxifen-treated
and vehicle-treated control Cxcr2-CKO mice were used to evaluate axons. Representa-
tive EM images from JHMV-infected mice treated with vehicle depict axons with very
little to no myelin sheath (Fig. 6A). Remyelinated axons in tamoxifen-treated JHMV-
infected Cxcr2-CKO mice were identiﬁed by thin myelin sheaths, in contrast to the
thicker myelin sheath detected on a normal myelinated axon (Fig. 6B). In vehicle-
FIG 6 Remyelination is increased following Cxcr2 ablation in oligodendroglia. Spinal cords were removed
at day 28 p.i. from JHMV-infected mice treated with either vehicle control or tamoxifen. (A and B)
Representative EM images from vehicle-treated mice depict demyelinated axons (black arrows) (A),
whereas in tamoxifen-treated mice, remyelinated axons (blue arrows) were present (B). Normal myelin-
ated axons (yellow arrows) are also shown. Magniﬁcations, 1,200. Analysis was performed in ventral
and lateral white matter columns of spinal cords isolated from experimental mice. (C) Scatter plot
depicting the g ratios of individual axons from vehicle- and tamoxifen-treated mice as a function of
axonal diameter. (D) Calculation of the g ratio of vehicle-treated Cxcr2-CKO mice (0.87 0.006, n 4
mice; 297 axons randomly selected from a total of 25 ﬁelds) and tamoxifen-treated Cxcr2-CKO mice
(0.78 0.006, n 5 mice; 493 axons randomly selected from a total of 34 ﬁelds) indicates a signiﬁcant
(P 0.05) reduction in the g ratios in tamoxifen-treated mice compared to the vehicle-treated controls.
(E) Scatter plot depicting the myelin thickness of individual axons from vehicle- and tamoxifen-treated
mice as a function of axon diameter. (F) Quantiﬁcation of myelin thickness in vehicle-treated mice
(0.23 m 0.008 m) and tamoxifen-treated mice (0.35 m  0.007 m) indicated a signiﬁcant
(P 0.01) increase in myelin thickness in tamoxifen-treated mice compared to the vehicle-treated
controls. The results are derived from two independent experiments, and the data in panels D and F are
presented as the mean  SEM.
CXCR2 and Myelin Repair Journal of Virology
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treated Cxcr2-CKO mice, there was an overall increase of demyelinated axons and fewer
remyelinated axons compared to tamoxifen-treated Cxcr2-CKO mice. To more accu-
rately quantitate these differences, we quantiﬁed both the g ratio and the myelin
thickness in infected mice. Tamoxifen-induced ablation of Cxcr2 on oligodendroglia
resulted in a g ratio (0.78 0.006, n 5 mice) signiﬁcantly (P 0.05) lower than that in
control mice (0.87 0.006, n 4 mice) (Fig. 6C and D). In addition, there was a
corresponding signiﬁcant (P 0.01) increase in myelin thickness in tamoxifen-treated
Cxcr2-CKO mice compared to vehicle-treated mice (Fig. 6E and F). Collectively, these
ﬁndings indicate that selective ablation of Cxcr2 in oligodendroglia enhances remyeli-
nation following JHMV-induced demyelination.
Small-molecule targeting of CXCR2 has been shown to enhance the maturation of
cultured oligodendrocyte progenitor cells (OPCs) to mature myelin-producing oligo-
dendroglia (58). To better understand how tamoxifen-mediated targeting of Cxcr2
within oligodendroglia led to an increase in remyelination, we stained for NG2, a
marker associated with OPCs, and GST-, which is normally associated with mature
myelin-producing oligodendrocytes in the spinal cords of experimental mice. There was
a signiﬁcant (P 0.01) decrease in NG2-positive cells in the spinal cords of tamoxifen-
treated mice compared to the vehicle controls (Fig. 7A to C). Conversely, we detected
an increase in the numbers of GST--positive cells in tamoxifen-treated mice compared
to the controls (Fig. 7D to F). These ﬁndings argue that targeted ablation of Cxcr2 within
oligodendrocytes increases the numbers of mature oligodendrocytes and that this
correlates with a diminished pool of OPCs and, correspondingly, an increase in remy-
elination.
DISCUSSION
Chemokine signaling networks that are associated with chronic CNS diseases, such
as MS, or persistent viral infections are thought to amplify disease severity by attracting
FIG 7 Cxcr2 ablation increases the numbers of mature oligodendrocytes in JHMV-infected mice. JHMV-infected
Cxcr2-CKO mice were treated with vehicle or tamoxifen, and at day 28 p.i. the animals were sacriﬁced and the spinal
cords were removed. Representative NG2 (A, B) and GST- (D, E) staining in control (n 5) and tamoxifen-treated
(n 4) mice is shown. Quantiﬁcation reveals reduced numbers of NG2-positive cells in tamoxifen-treated mice (C)
and increased numbers of dual-positive GST--positive cells in tamoxifen-treated mice (F) compared to vehicle-
treated mice. Data represent those from 2 independent experiments, and signiﬁcance was measured using an
unpaired 2-tailed Student’s t test. **, P 0.01; ***, P 0.001. DAPI, 4=,6-diamidino-2-phenylindole.
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targeted populations of leukocytes into the CNS (59). One chemokine pathway that is
emerging as important in chronic CNS disease involves the CXCR2 receptor and its
cognate ELR-positive chemokine ligands CXCL1, -2, and -3 and CXCL5, -6, -7, and -8.
CXCR2 is highly expressed on circulating neutrophils, enabling these cells to rapidly
migrate to the blood-brain barrier (BBB) in response to CNS-derived ELR-ligand expres-
sion, whereby these cells participate in degrading components of the BBB. Evidence for
a proinﬂammatory role of neutrophils in chronic neurologic disease is supported by the
work of Segal and colleagues (8), who have shown that genetic silencing or antibody-
mediated blockade of CXCR2 in mice following PLP-induced EAE results in reduced
clinical disease and relapses as a result of limiting BBB permeability. Within the context
of acute viral infection of the CNS, we have previously reported that antibody-mediated
neutralization of CXCR2 during JHMV infection enhances disease (54). This outcome
was a result of reduced neutrophil and monocyte trafﬁcking, as these cells are critical
in permeabilizing the BBB, which subsequently allows the penetration of virus-speciﬁc
T cells in the parenchyma to combat viral replication.
In addition to being expressed on circulating myeloid cells, CXCR2 is also expressed
on neurons (45, 46), cerebral endothelial cells (60, 61), as well as resident glia, including
microglia (45, 47) and oligodendrocytes (13, 14, 22, 25, 62, 63). Further, addition of
IFN- to cultured OPCs derived from mouse neural progenitor cells results in apoptosis,
while inclusion of the CXCL1 protein blocks OPC apoptotic death (14). CXCR2 also
inﬂuences OPC proliferation and differentiation (21) as well as controls the migration of
spinal cord OPCs during development (22). Ablation of Cxcr2 results in a paucity of OPC
numbers and structural misalignments that persist into adulthood in the mouse and
manifest as reduced numbers of mature oligodendrocytes and total myelin within the
white matter (23).
The functional role of CXCR2 signaling in mouse models of demyelination within the
CNS is enigmatic. Some ﬁndings suggest that the CXCR2 signaling axis downregulates
myelin production by oligodendrocytes (64), while we have reported that CXCR2
signaling is a survival mechanism for OPCs needed to halt the apoptosis induced by
cytotoxic factors secreted during an inﬂammatory response (14, 37, 63, 65). With
regards to CXCR2 signaling and survival, these studies were performed using either
antibody targeting of CXCR2 or germ line Cxcr2	/	 mice, and this opens the possibility
of CXCR2 signaling on other cell types, either resident or immune cells, in augmenting
experimental outcomes. Previously, members of our group (24) used bone marrow
chimeric mice to partition the contribution of CXCR2 expression on either hematopoi-
etic or CNS-derived cells. Adoptive transfer of hematopoietic cells derived from the
bone marrow of Cxcr2/ mice into Cxcr2	/	 mice enabled the study of both EAE- and
cuprizone-mediated demyelination and demonstrated increased oligodendrocyte dif-
ferentiation in both models of demyelination, suggesting that CXCR2 may be an
inhibitory signaling cue for myelin repair (24). CXCR2 antagonism via neutralizing
antibodies enhanced oligodendrocyte differentiation and clinical recovery during EAE,
further supporting a detrimental role for CXCR2 signaling within the CNS in mouse
models of chronic inﬂammatory demyelinating disease (58). Conversely, inducible
overproduction of CXCL1 by astrocytes reduced EAE clinical disease, although it was
unclear whether increased levels of CXCL1 directly affected oligodendrocyte biology or
modulated immune cell recruitment into the CNS (65). We have recently shown that
induced expression of CXCL1 resulted in increased demyelination mediated by neu-
trophils in both JHMV and EAE models of neurologic disease (18, 19). In addition,
previous work from our laboratories employing antibody-mediated targeting of CXCR2
shows that blocking signaling in JHMV-infected mice increases the severity of demy-
elination, arguing for a protective role for CXCR2 in a model of virus-induced demy-
elination, as previously discussed (37). However, whether this is a direct effect of
blocking CXCR2 signaling on oligodendroglia and/or other CNS resident cells is un-
known. Given the various resident cell types within the CNS that express CXCR2 as well
as inﬂammatory myeloid cells expressing CXCR2, it is difﬁcult to accurately assign a
speciﬁc role for CXCR2 in protecting spinal cord oligodendroglia from apoptosis using
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an antibody-mediated targeting approach. It may be possible that anti-CXCR2 treat-
ment of JHMV-infected mice altered the signaling responses on other CXCR2-positive
resident cells and/or inﬁltrating immune cells and that this contributed to the increased
clinical disease severity associated with more severe demyelination and oligodendro-
cyte death.
Our present study used a more incisive genetic model to further our understanding
of how CXCR2 signaling on oligodendrocytes affects neurologic disease in a preclinical
animal model of MS. Using this genetic approach, our ﬁndings indicate that targeted
deletion of Cxcr2 occurs in oligodendrocytes both in vitro and in vivo. In addition, our
previous work indicates that CXCR2 expression on neutrophils is important in host
defense by allowing these cells to participate in increasing the permeability of the
blood-brain barrier, allowing access of virus-speciﬁc T cells into the CNS to control virus
replication. However, tamoxifen treatment did not diminish CXCR2 expression on
neutrophils, as determined by ﬂow cytometry. In addition, we have previously reported
that antibody targeting of CXCR2 during acute JHMV-induced disease limits neutrophil
migration to the CNS, resulting in increased mortality correlating with impaired T cell
access to CNS and increased viral titers (54).
Targeting of CXCR2 in Cxcr2-CKO mice was selective to oligodendroglia and did not
affect myelin thickness in adult naive animals. These ﬁndings allowed us to move
forward and assess how silencing of Cxcr2 on oligodendrocytes inﬂuences neuroin-
ﬂammation, demyelination, and remyelination in response to intracerebral inoculation
with the neurotropic virus JHMV. Targeting of CXCR2 signaling on oligodendroglia did
not dampen the accumulation of either myeloid cells or lymphocytes; the inﬁltration of
virus-speciﬁc T cells was not affected, and this correlated with the ability to efﬁciently
control viral replication within the CNS. We also determined that expression of proin-
ﬂammatory genes within the CNS was not impacted in response to tamoxifen-mediated
silencing of Cxcr2 on oligodendrocytes, further supporting the notion that chemokine
signaling through CXCR2 oligodendrocytes does not inﬂuence neuroinﬂammation.
Sterile immunity is not acquired in JHMV-infected mice, and persistent virus is enriched
within glial cells present within white matter tracts, resulting in an immune-mediated
demyelinating disease mediated by activated T lymphocytes as well as microglia and
macrophages (28). We did not detect differences in the severity of demyelination in
tamoxifen-treated JHMV-infected Cxcr2-CKO mice from that in the controls, and these
results are consistent with our ﬁndings that selective ablation of Cxcr2 in oligodendro-
cytes does not impact neuroinﬂammation.
We observed increased numbers of mature GST- oligodendrocytes along with
reduced numbers of NG2-positive cells representing OPCs in the spinal cords of
Cxcr2-CKO mice treated with tamoxifen compared to the vehicle-treated controls.
Through EM analysis of the spinal cords of the experimental mice, we determined that
an increase in the remyelination of axons occurred following targeting of CXCR2 and
that this correlated with an increased myelin thickness compared to that in control
animals. Collectively, these ﬁndings support the concept that targeted ablation of
CXCR2 on oligodendroglia in adult mice may enhance the maturation of OPCs into
myelin-producing oligodendrocytes (25, 58).
Previously, members of our group (25) generated mice in which Cxcr2 was selec-
tively ablated in oligodendrocytes. Similar to the ﬁndings for the animals that we report
here, Cxcr2 was silenced within oligodendroglia in adult mice upon tamoxifen treat-
ment (25). Employing toxin models of demyelination, the authors clearly showed
enhanced remyelination in animals in which CXCR2 signaling in oligodendrocytes was
inhibited, arguing for an important role for this chemokine receptor in inﬂuencing
oligodendrocyte biology. Our ﬁndings would suggest that the inﬂuence of CXCR2
signaling on oligodendroglia is not model dependent, as remyelination is observed in
both toxin and viral models of demyelination. Our ﬁndings are consistent with those of
Kerstetter et al. (58), who showed that treatment of mice with MOG35–55-induced EAE
with small-molecule antagonists speciﬁc for CXCR2 resulted in improved motor skills
that correlated with diminished white matter damage associated with enhanced re-
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myelination, arguing that CXCR2 may be a relevant therapeutic target for the treatment
of demyelinating diseases. We would not argue with this conclusion but suggest that
the small-molecule antagonists employed in this study may be targeting other cell
types, e.g., resident glia and/or inﬂammatory cells, including neutrophils, resulting in
improved clinical and histologic outcomes.
MATERIALS AND METHODS
Mice and tamoxifen treatment. Plp-Cre-ER(T)::Cxcr2ﬂoc/ﬂoc mice were crossed to mice of the reporter
strain B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J (stock number 007909; The Jackson Laboratory) to gen-
erate Plp-Cre-ER(T)::Cxcr2ﬂoc/ﬂoc::R26-stop-Td/	 (Cxcr2-CKO) mice. Tamoxifen was prepared by resuspend-
ing it at 10 mg/ml in prewarmed sesame seed oil. Four-week-old Cxcr2-CKO mice received either 1 mg/ml
tamoxifen or vehicle (control) twice daily for 5 days via intraperitoneal (i.p.) injection, rested for 2 weeks,
and subsequently infected intracranially with JHMV (43, 44).
Viral infection. Age-matched 5- to 6-week-old Cxcr2-CKO mice were infected i.c. with 250 PFU of
JHMV in 30 l of sterile Hanks balanced salt solution (HBSS); sham-infected animals received 30 l HBSS
via i.c. injection (56, 66). For viral titer analysis, one half of each brain or whole spinal cord was
homogenized and used in a plaque assay as previously described (19, 67). Clinical disease severity was
assessed using a previously described scoring system (19, 67). All animal experiments were approved by
the University of Utah Institutional Animal Care and Use Committee per protocol no.16-09008.
Primary oligodendrocyte cultures. Cortices from postnatal day 1 Cxcr2-CKO mice were dissected
and processed according to previously published protocols (68). In brief, following removal of the
meninges, cortical tissue was minced with a razor and placed in prewarmed Dulbecco modiﬁed Eagle
medium (DMEM) containing papain in order to completely dissociate the tissue. Following further
aspiration through a Pasteur pipette, single-cell suspensions were added to poly-D-lysine-coated culture
ﬂasks and grown for 9 days in DMEM supplemented with 10% fetal bovine serum. Th ﬂasks were then
transferred to an orbital shaker in a 5% CO2 tissue culture incubator and shaken for approximately 16 h
at 220 rpm in order to remove loosely adherent oligodendroglia. Medium containing OPCs was trans-
ferred to 10-cm dishes for 30 min to remove strongly adherent astroglial contaminants. Oligodendroglia
were transferred to a 1- ml conical tube and centrifuged at 300 g for 5 min. The cells were counted
and plated onto Matrigel-coated Nunc Lab-Tek II chamber slides (Thermo Fisher Scientiﬁc, Waltham,
MA) at 50,000 OPCs per chamber in N2 medium supplemented with 3,3=,5-triiodo-L-thyronine
sodium salt hydrate (T3; Sigma, St. Louis, MO). After 2 days, fresh medium supplemented with
(Z)-4-hydroxytamoxifen (4-OHT; Sigma, St. Louis, MO) at 100 nM was used to induce Cre-mediated
recombination. Cells were cultured for an additional 6 days.
Cell isolation and ﬂow cytometry. Flow cytometry was performed to identify inﬂammatory cells
entering the CNS using established protocols (67, 69). In brief, single-cell suspensions were generated
from tissue samples by grinding with frosted microscope slides. Immune cells were enriched via a 2-step
Percoll cushion (90% and 63%), and the cells at the interface of the two Percoll layers were collected.
Before staining with ﬂuorescent antibodies, isolated cells were incubated with anti-CD16/32 Fc block (BD
Biosciences, San Jose, CA) at a 1:200 dilution. Immunophenotyping was performed using commercially
available antibodies speciﬁc for the following cell surface markers: F4/80 (Serotec, Raleigh, NC), CD4, CD8,
Ly6G, and CD11b (BD Biosciences, San Jose, CA), and Ly6C (eBioscience, San Diego, CA). The indicated
ﬂow cytometric gating strategies were employed for following inﬂammatory cells isolated from the CNS:
neutrophils (CD45hi CD11b Ly6G), monocytes (CD45hi CD11b Ly6C Ly6G	), macrophages (CD45hi
CD11b F4/80), and microglia (CD45lo CD11b F4/80lo). Allophycocyanin (APC)-conjugated rat anti-
mouse CD4 and a phycoerythrin (PE)-conjugated tetramer speciﬁc for the CD4 immunodominant epitope
present within the JHMV matrix (M) glycoprotein spanning amino acids 133 to 147 (the M133–147
tetramer) were used to determine total and virus-speciﬁc CD4 cells, respectively (19, 56); APC-
conjugated rat anti-mouse CD8a and a PE-conjugated tetramer speciﬁc for the CD8 immunodominant
epitope present in the spike (S) glycoprotein spanning amino acids 510 to 518 (S510–518) were used to
identify total and virus-speciﬁc CD8 cells, respectively (19, 56). Samples were analyzed using a BD LSR
Fortessa X-20 ﬂow cytometer and analyzed with FlowJo software (Tree Star Inc.).
PCR array and semiquantitative RT-qPCR. Proinﬂammatory gene expression was determined using
a mouse cytokine and chemokine RT2 Proﬁler PCR array (Qiagen Inc., Valencia, CA), which included the
following genes: chemokine genes Ccl1, Ccl11, Ccl12, Ccl17, Ccl19, Ccl2, Ccl20, Ccl22, Ccl24, Ccl3, Ccl4, Ccl5,
Ccl7, Cx3cl1, Cxcl1, Cxcl10, Cxcl11, Cxcl12, Cxcl13, Cxcl16, Cxcl3, Cxcl5, Cxcl9, Pf4, Ppbp, and Xcl1; interleukin/
cytokine genes Il10, Il11, Il12a, Il12b, Il13, Il15, Il16, Il17a, Il17f, Il18, Il1a, Il1b, Il1rn, Il2, Il21, Il22, Il23a, Il24,
Il27, Il3, Il4, Il5, Il6, Il7, Il9, Adipoq (Acrp30), Ctf1, Hc, Mif, Spp1, Tgfb2, Ccl19, Il10, Il11, Il12a, Il12b, Il13, Il18,
Il2, Il22, Il23a, Il24, Il4, Il6, and Tgfb2; interferon genes Ifna2 and Ifng; growth factor genes Bmp2, Bmp4,
Bmp6, Bmp7, Cntf, Csf1, Csf2, Csf3, Gpi1, Lif, Mstn, Nodal, Osm, Thpo, and Vegfa; and TNF receptor
superfamily member genes Cd40lg, Cd70, Fasl, Lta, Ltb, Tnf, Tnfrsf11b, Tnfsf10, Tnfsf11, and Tnfsf13b. For
reverse transcription-quantitative PCR (RT-qPCR) analysis, total cDNA from the brains of JHMV-infected
mice at day 7 p.i. was generated via SuperScript III reverse transcriptase (Life Technologies, Carlsbad, CA)
after homogenization in the TRIzol reagent (Life Technologies, Carlsbad, CA).
Histology. Mice were euthanized at deﬁned times points according to approved IACUC protocol
no.16-09008, and the length of the spinal cord extending from thoracic vertebrae 6 to 10 was
cryoprotected in 30% sucrose, cut into 1-mm transverse blocks, processed so as to preserve the
craniocaudal orientation, and subsequently embedded in OCT (VWR, Radnor, PA, USA). Eight-
micrometer-thick coronal sections were cut, sections were stained with hematoxylin/eosin (H&E) in
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combination with Luxol fast blue (LFB), and between 4 and 8 sections per mouse were analyzed. Areas
of total white matter and demyelinated white matter were determined with ImageJ software, and
demyelination was scored as the percentage of total demyelination from the spinal cord sections
analyzed (55, 67, 70).
Quantitative immunocytochemistry. For cultured oligodendroglia, cells were ﬁxed for 20 min in 4%
paraformaldehyde before being blocked with species-appropriate serum. Cells were then stained with
mouse anti-O1 (1:50 dilution; eBioscience, San Diego, CA) overnight at 4°C, followed by a secondary stain
with ﬂuorescently labeled secondary antibodies. Control sections were incubated with an appropriate
secondary antibody in the absence of primary antibody. Cell morphology and the presence of nuclei
were criteria for determining cells dual positive for tdTomato and O1. TdTomato red expression in
O1-positive oligodendrocyte cultures was quantiﬁed by random selection of 10 imaging sections (20
magniﬁcation) from three independently isolated oligodendrocyte-enriched cultures. The slides were
deidentiﬁed and read independently by two investigators.
Quantitative immunohistochemistry. Spinal cords (ranging from thoracic vertebrae 6 to 10)
were removed from experimental mice at deﬁned times p.i. and processed as described above. For
immunohistochemical analysis, 8-m sections were desiccated at room temperature for 2 h before
beginning the staining process. The slides were then washed in phosphate-buffered saline (PBS) and
blocked with species-appropriate serum for 1 h at room temperature. Rabbit anti-GST- (1:1,000
dilution; MBL Life Science, Woburn, MA), rabbit anti-Olig2 (1:500 dilution; Millipore Corp., Temecula,
CA), rabbit anti-NG2 (1:200 dilution; Millipore Corp., Temecula, CA), mouse anti-MAP2 (1:200 dilution;
Sigma-Aldrich, St. Louis, MO), and rabbit anti-IBA1 (1:500 dilution; Wako Chemicals, Inc., Richmond,
VA) were used to stain the slides overnight at 4°C, the slides were subsequently washed in PBS, and
appropriate secondary ﬂuorescently conjugated antibodies were used for detection of targeted
antigens. Control sections were incubated with appropriate secondary antibody in the absence of
primary antibody.
Quantitative analysis of NG2- and GST--positive cells was performed by analyzing spinal cords
from Cxcr2-CKO mice treated with tamoxifen (n 4) from two independent experiments and
performed in a blind fashion, and the results were read by two investigators. Coronal spinal cord
sections (ranging from 4 to 10 sections per mouse) were used to count cells positive for either NG2
or GST- in each experimental group. Microscopy was performed on a Nikon A1 confocal laser
microscope (University of Utah Cell Imaging Core Facility). To phenotype tdTomato-positive cells,
spinal cords from tamoxifen-treated mice (n 5) were used to detect cells dual positive for
tdTomato and cellular markers for neurons (MAP2), macrophage/microglia (IBA1), or oligodendroglia
(Olig2 and GST-). Coronal spinal cord sections (ranging from 2 to 5 sections per mouse) were used
to count dual-positive cells.
EM. For electron microscopy (EM) analysis of spinal cords (ranging from thoracic vertebrae 6 to 10),
experimental mice were sacriﬁced and underwent cardiac perfusion with 0.1 M cacodylate buffer
containing 2% paraformaldehyde–2.5% glutaraldehyde. Serial ultrathin sections of spinal cords embed-
ded in Epon epoxy resin were stained with uranyl acetate-lead citrate and analyzed as previously
described (36, 55, 56, 71). Images at 1,200 magniﬁcation were analyzed for the g ratio and myelin
sheath thickness. In adult animals, there is a relationship between axon circumference and total myelin
sheath thickness (number of lamellae), expressed by the g ratio (axon diameter/total ﬁber diameter); in
remyelination, this relationship changes such that myelin sheaths are abnormally thin for the axons that
they surround (72). An abnormally thin myelin sheath relative to the axonal diameter was used as the
criterion for oligodendrocyte remyelination. The absence of a myelin sheath was used as the criterion for
demyelination. Analysis was performed in ventral and lateral white matter columns of spinal cords
isolated from experimental mice. For vehicle-treated mice, a total of 297 axons were counted (n 4
mice) from a total of 25 randomly selected ﬁelds, and for tamoxifen-treated mice, a total of 493 axons
were counted (n 5 mice) from a total of 34 randomly selected ﬁelds. EM images were analyzed using
ImageJ software.
Statistics. For RT-qPCR quantiﬁcation, the fold change in expression was determined by normalizing
the expression of each sample to that of -actin and then quantifying the fold change in expression
relative to that in naive mice. A log-rank (Mantel-Cox) test was used for survival curve analysis.
Comparisons of two groups were analyzed by two-tailed Student’s t tests unless otherwise indicated.
Data are reported as the mean  standard error of the mean (SEM), with a P value of 0.05 being
considered signiﬁcant.
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